NEW YORK (GenomeWeb News) – Metamark Genetics today announced that Massachusetts has licensed the company's laboratory as it prepares to launch its prognostic assay for managing patients with prostate cancer.

The lab in Cambridge, Mass. is CLIA-certified, but a handful of states require additional regulatory approval before certain tests can be performed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.